Agenus releases corporate overview presentation on botensilimab-balstilimab neoadjuvant colon cancer data
AGEN•Market opportunity and financing
The company estimated the US addressable market at above $7 billion, based on about 38,000 eligible high-risk Stage II and Stage III MSS patients annually.
A PIPE financing in July 2026 is expected to fund ROBBIN costs and operations through end-2031, assuming full warrant exercise.
Corporate overview highlights neoadjuvant colon cancer data
Agenus published a corporate overview highlighting botensilimab with balstilimab in neoadjuvant MSS colon cancer.
- IST data from NEST and UNICORN in 38 MSS patients showed about 30% pCR, about 40% MPR, and 100% EFS at 9-18 months.
- Registrational Phase 3 “ROBBIN” is planned with FDA alignment, n=850, 1:1 randomization, and primary endpoint EFS.
- First patient in is expected by Q1 2027.
